EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Why Osteosarcopenia Matters: Clinical and Investigative Implications

Erik Luiz Bonamigo iD, Marcella Nora Maia, Renata Pinheiro Cavallaro de Oliveira, Régis Gemerasca Mestriner iD, Ivan Aprahamian, Gustavo Duque iD

European Journal of Clinical Investigation · 2026-05 · 56 (5)

DOI: 10.1111/eci.70221 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 14.05.2026. Verfasst von Erik Luiz Bonamigo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bone, Muscle & Geroscience Group, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Sarcopenia, Osteoporosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteosarcopenia, the combination of osteoporosis and sarcopenia, is a geriatric syndrome linked to functional decline, falls, and fragility fractures. The interaction among bone, muscle, and their shared pathophysiology is driven by mechanical, metabolic, and hormonal factors. With global population aging and increasing healthcare demands, early detection of osteosarcopenia has become essential.

Methods

This narrative review summarizes current evidence on the epidemiology, pathophysiology, clinical findings, diagnosis, and treatment of osteosarcopenia, based on international consensus guidelines, large‐scale population cohorts, interventional studies, and translational research.

Results

The occurrence of osteosarcopenia reflects the combined impact of low bone mineral density (BMD), loss of muscle mass and strength, and age‐related metabolic changes such as chronic inflammation, lipotoxicity, and disruptions in tryptophan (TRP) metabolism. Diagnostic evaluation requires combining bone assessment through Dual‐energy X‐ray Absorptiometry with functional and structural evaluations of sarcopenia, using criteria established by the European and global consensus on Sarcopenia. Management includes established pharmacological therapies for osteoporosis, while for sarcopenia, to date, it is mainly based on resistance exercise and adequate protein intake. Supplementation with protein, leucine, vitamin D, calcium, and creatine may further enhance outcomes. Promising emerging strategies include hormonal modulators, anti‐inflammatory agents, metabolic pathway–oriented therapies, and cell‐based interventions.

Conclusions

Osteosarcopenia significantly raises the risk of falls, fractures, disability, and death. Effective management requires a comprehensive treatment approach that targets both bone and muscle decline. Further research is necessary to refine diagnostic criteria and assess the success of combined interventions through clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaOsteoporosisHumansBone DensityResistance TrainingAbsorptiometry, PhotonVitamin DDietary SupplementsBone Density Conservation AgentsTryptophan

Stichwörter der Autor:innen

agingbone–muscle crosstalkfrailtyosteoporosisosteosarcopeniasarcopenia

Substanzen

Vitamin DBone Density Conservation AgentsTryptophan

Autor:innen und Institutionen

  • Bone, Muscle & Geroscience Group, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Hospital São Lucas da, Pontifícia Universidade Católica Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
  • Departamento de Medicina Interna, Divisão de Geriatria, Faculdade de Medicina de Jundiaí, Jundiaí, São Paulo, Brazil.
  • Instituto de Geriatria e Gerontologia (IGG-PUCRS), Pontifícia Universidade Católica Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
  • Division of Geriatric Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Erik Luiz Bonamigo, Régis Gemerasca Mestriner, Gustavo Duque

Zitieren

APA

Bonamigo, E. L., Maia, M. N., Pinheiro Cavallaro de Oliveira, R., Gemerasca Mestriner, R., Aprahamian, I., & Duque, G. (2026). Why Osteosarcopenia Matters: Clinical and Investigative Implications. European Journal of Clinical Investigation, 56(5). https://doi.org/10.1111/eci.70221

Vancouver

Bonamigo EL, Maia MN, Pinheiro Cavallaro de Oliveira R, Gemerasca Mestriner R, Aprahamian I, Duque G. Why Osteosarcopenia Matters: Clinical and Investigative Implications. European Journal of Clinical Investigation. 2026;56(5). doi:10.1111/eci.70221

BibTeX
@article{Bonamigo2026,
  author = {Bonamigo, Erik Luiz and Maia, Marcella Nora and Pinheiro Cavallaro de Oliveira, Renata and Gemerasca Mestriner, Régis and Aprahamian, Ivan and Duque, Gustavo},
  title = {Why Osteosarcopenia Matters: Clinical and Investigative Implications},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {5},
  doi = {10.1111/eci.70221}
}
Kostenlos starten →